Anti-Viral Drugs Market
Encouraging Healthcare Policies and Rising Prevalence of Viral Diseases Spurs Demand for Anti-Viral Drugs across the Globe
Anti-Viral Drugs Market by Product Type, End User & Region - Forecast 2022 - 2032
Anti-Viral Drugs Market Snapshot (2022-2032)
[298 Pages Report] The global anti-viral drugs market is expected to be valued at US$ 59,596.8 Million in 2022. The induction of the generic version of antiviral medicines and rising awareness about the availability of various vaccines for viral infections is affecting the growth throughout the forecast period. The overall demand for Anti-Viral Drugs is projected to grow at a CAGR of 3.9% between 2022 and 2032, totaling around US$ 87,675.36 Million by 2032.
|
Data Points |
Key Statistics |
|
Anti-Viral Drugs Market Value 2022 |
US$ 59,596.8 Million |
|
Anti-Viral Drugs Market Projected Value (2032) |
US$ 87,675.36 Million |
|
Anti-Viral Drugs Market CAGR (2022-2032) |
3.9% |
Anti-viral drugs are medicines that are used especially for treating viral infections. Most anti-viral drugs are used for particular viral infections, similar to antibiotics, while a broad-spectrum anti-viral drug is effective against a varied range of viruses. Antiviral drugs do not kill their target pathogen, instead, they inhibit the development of those viruses.
The global anti-viral drugs market is projected to register a moderate growth rate in the pharmaceutical market and which is anticipated to increase due to a rise in awareness level, an increase in the diseased population, and the introduction of new drugs with improved efficacy.
Some major patents are reaching their expiry during the forecast periods, such as Combivir, Sustiva, Tenofovir, Tamiflu, Relenza, and Telbivudine. The patent expiries of these blockbuster drugs are expected to trigger generic competition in the antivirals therapeutics market, which will make the market more competitive.
The late-stage pipeline drugs are expected to enter the market, which will positively impact the market. Most antivirals are considered comparatively harmless to the host and therefore are used to treat infections. They are different from viricides, which are not used for medication but can destroy or deactivate virus particles, either outside or inside the body. The anti-viral drugs are used in the treatment of patients suffering from herpes viruses, HIV, influenza A, and B viruses, and hepatitis B and C viruses.
Let us know your requirement to get
100% FREE customization
Anti-Viral Drugs Demand Analysis (2016 to 2021) Vs Market Outlook (2022 to 2032)
The global demand for Anti-Viral Drugs is projected to increase at a CAGR of 3.9% during the forecast period between 2022 and 2032, reaching a total of US$ 87.67 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 3.4~%.
During the historic outlook, the biggest driver of the overall anti-viral drugs market was Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for more than half the share of the market in 2021. According to WHO, in 2021, several patients living with HIV are 38.4 million, and 650k people acquired the disease in the same year.
Nearly four out of five people were freshly put on treatment in sub-Saharan Africa. In 21 African countries with a high burden of HIV, two out of three people in need are receiving treatment, and two out of three positive pregnant women are receiving antiretroviral drugs to prevent HIV transmission to their infants. The introduction of solid R&D activities, newer and advanced treatments, and formulations, such as vaccines, and combination therapy are projected to fuel the market growth of anti-viral drugs over the forecast period.
Which Drivers underpin Anti-Viral Drugs Industry Expansion?
The increasing commonness of viral infections such as HIV, Herpes, Influenza, and others are expected to upsurge the demand for antiviral medicines throughout the forecast period. For instance, according to UNAIDS, in 2020, more than 37 billion individuals were living with HIV across the globe. Out of these, approximately 1.5 billion new people acquired HIV infection in 2020. Overall, the COVID-19 pandemic has pointedly accelerated the market growth in 2021 whereas, a negative impact of the pandemic has been detected for other applications of antiviral drugs.
Owing to the solid R&D activities, newer and advanced treatments and formulations, such as vaccines, combination therapy, and others, are being introduced in the market, and the demand is anticipated to upsurge. Hence, strong R&D is one of the crucial factors in the anti-viral drugs market growth
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich Factors are limiting the Growth of the Anti-Viral Drugs Market?
Several factors hampering the market expansion of Anti-Viral Drugs include high risk of failure, high cost of R&D and therapy, and government austerity. However, swelling usage of natural products and the high cost of developing drugs are the key challenges faced by the market.
Region-wise Insights
Will North America Hold a Significant Position in the Global Anti-Viral Drugs Market?
In terms of market contribution, North America acquires the largest share in the revenue collection across the globe, accounting for 38.7% share in 2022. As per the recent analysis by Future Market Insights, the region is anticipated to maintain its dominance during the assessment period 2022-2032. The United States and Canada are estimated to be the largest shareholders in the regional revenue generation.
The market decline can be attributed to the loss of market exclusivity of patented drugs, mounting vaccination rates against viral infections, and government initiatives to minimize the prevalence of viral infections.
For instance, the U.S. government is responsible for several measures including funding and grants in infectious diseases programs and encouraging the R&D activities of innovative therapies to manage viral infections.
How Will Growth of the European Anti-Viral Drugs Market unfold?
Based on the geographies, European is the second-largest region, acquiring a 14.9% share in the Anti-Viral Drugs market. During the forecast period, the region is estimated to witness moderate growth, backed by soaring investments in the development of new drugs and therapies. This market growth is also attributed to the easy approval and promising healthcare policies by several governments.
In April 2022, European Medicines Agency, the European Union’s drug regulator signed off on emergency usage of Merck’s Covid antiviral pill for adults who get tested positive as it prepares to decide on full approval by the year’s end.
In July 2021, GSK and Vir announced a Joint Procurement Agreement (JPA) with the European Commission to supply up to 220,000 doses of sotrovimab. Following the grant of the marketing authorization in the EU, Member States participating in the JPA can now order sotrovimab to support their pandemic responses. These initiatives are likely to fuel the market growth of Anti-Viral Drugs in the coming years.
How the APAC region is Bolstering the Demand for Anti-Viral Drugs?
In the Asia Pacific, the market for antiviral drugs is anticipated to witness the fastest growth rate throughout the forecast period. The exponential growth of the market can be attributed to the rising prevalence and treatment rate of viral infections, emerging healthcare infrastructure in the region, and growing awareness among people regarding infectious diseases.
Besides, the strong presence of generic pharmaceutical manufacturing companies in India, China, and other South Asian countries and the rising geriatric population in the region are some of the principal driving factors of the segment.
The introduction of new and innovative strategies in the emerging economies is also likely to boost the demand for Anti-Viral Drugs over the coming decade.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Category-wise Insights
By Application, Which Anti-Viral Drugs Category Will Remain Prominent?
The global anti-viral drugs market is segmented based on product type and end-user. The HIV segment captures the majority share in terms of market revenue generation. and held the largest revenue share of 44.1% in 2021. The segment is projected to observe the fastest growth rate over the forecast period. The rising prevalence of HIV infection associated with a high treatment rate, availability of branded drugs, and government initiatives to upsurge the treatment rate is projected to stimulate the market at a higher growth rate.
For instance, in 2019, the U.S. government introduced the Ending the HIV Epidemic (EHE) plan to end the HIV epidemic in the country by 2032. The initiative seeks to decrease HIV infections and enhance the diagnosis and treatment rate in the U.S. Furthermore, the existence of strong pipeline drugs for HIV infection will also fuel market growth throughout the conjecture period.
The hepatitis segment held the second-largest revenue share in 2021. Escalating vaccination against hepatitis A and B is affecting the growth adversely. Besides, the occurrence of the COVID-19 pandemic has significantly augmented the growth of the other segment in 2020.
The Start-Up Ecosystem: How key Players are Opening Frontiers for Future Growth?
- Founded in 2010, New American Therapeutics is a US-based specialty pharmaceutical company. The company acquires, markets, and develops therapeutic products for infectious diseases. It develops Denavir, an antiviral topical drug for the treatment of recurrent herpes labialis in adults and children 12 years of age and older. Denavir was acquired from Novartis in 2010
- Founded in 2009, Adaptive Biotechnologies is a U.S based provider of clinical diagnostics, and drug discovery for immune diseases. The company's immune profiling sequencing technology immunoSEQ enables characterization of the immune system, helping scientists & clinicians in research and drug development. The company also offers clonoSEQ for monitoring Minimal Residual Disease (MRD) in blood-based cancers. Also, develops cell therapies, vaccines, and antibody molecules for infectious diseases.
Competitive Landscape: What are the Leading Players in the Anti-Viral Drugs Market Up to?
- In May 2022, Cipla Limited, in partnership with Genes2Me Pvt. Ltd., announced the commercialization of the 'RT-Direct' multiplex COVID-19 RT PCR Test kit in India. Cipla is increasing its diagnostics portfolio in an attempt to take more innovative and innovative solutions to the market.
- In May 2022, Abbott reached an agreement with the Food and Drug Administration on Monday to reopen the company's manufacturing plant in Michigan to help ease a nationwide shortage of baby formula, after the facility was closed due to bacterial contamination.
- In March 2022, Scripps Research, non-profit research and technology, drug discovery organization, and AbbVie Inc. established a strategic collaboration to investigate novel, immediate antiviral treatments for COVID-19.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 3.9% from 2022-2032 |
|
Market Value in 2022 |
US$ 59.59 Billion |
|
Market Value in 2032 |
US$ 87.67 Billion |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2017-2021 |
|
Forecast Period |
2022-2032 |
|
Quantitative Units |
Revenue in US$ Million and CAGR from 2022-2032 |
|
Report Coverage |
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
Key Segments Covered in the Anti-Viral Drugs Industry Analysis
Anti-Viral Drugs Market by Product type:
- Hepatitis-C antivirals
- HIV antivirals
- Herpes antivirals
- Hepatitis-B antivirals
- Influenza antivirals
- Others (Pneumonia, Flu, etc.)
Anti-Viral Drugs Market by End-user:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
Anti-Viral Drugs Market by Region:
- North America Anti-Viral Drugs Market
- Latin America Anti-Viral Drugs Market
- Europe Anti-Viral Drugs Market
- Asia Pacific Anti-Viral Drugs Market
- The Middle East & Africa Anti-Viral Drugs Market
Frequently Asked Questions
As of 2022, the Anti-Viral Drugs market is slated to reach a valuation of US$ 59.59 Billion .
From 2022-2032, sales of Anti-Viral Drugs are expected to grow at a 3.9% CAGR.
By 2032, Future Market Insights expects the Anti-Viral Drugs market to reach US$ 87.67 Billion.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Anti-Viral Drugs Market Analysis 2016-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2016-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Product Type, 2016-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Product Type, 2022-2032
5.3.1. Hepatitis-C Antivirals
5.3.2. HIV Antivirals
5.3.3. Herpes Antivirals
5.3.4. Hepatitis-B Antivirals
5.3.5. Influenza Antivirals
5.3.6. Others (Pneumonia, Flu, etc.)
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2016-2021
5.5. Absolute $ Opportunity Analysis By Product Type, 2022-2032
6. Global Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2016-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2022-2032
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Ambulatory Surgical Centers
6.4. Y-o-Y Growth Trend Analysis By End User, 2016-2021
6.5. Absolute $ Opportunity Analysis By End User, 2022-2032
7. Global Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2016-2021
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
8.2.1. By Country
8.2.1.1. US
8.2.1.2. Canada
8.2.2. By Product Type
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Product Type
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Product Type
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product Type
9.3.3. By End User
9.4. Key Takeaways
10. Europe Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. U.K.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Product Type
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By End User
10.4. Key Takeaways
11. Asia Pacific Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Rest of Asia Pacific
11.2.2. By Product Type
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By End User
11.4. Key Takeaways
12. MEA Anti-Viral Drugs Market Analysis 2016-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2016-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of MEA
12.2.2. By Product Type
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By End User
12.4. Key Takeaways
13. Key Countries Anti-Viral Drugs Market Analysis
13.1. US
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2021
13.1.2.1. By Product Type
13.1.2.2. By End User
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2021
13.2.2.1. By Product Type
13.2.2.2. By End User
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2021
13.3.2.1. By Product Type
13.3.2.2. By End User
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2021
13.4.2.1. By Product Type
13.4.2.2. By End User
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2021
13.5.2.1. By Product Type
13.5.2.2. By End User
13.6. U.K.
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2021
13.6.2.1. By Product Type
13.6.2.2. By End User
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2021
13.7.2.1. By Product Type
13.7.2.2. By End User
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2021
13.8.2.1. By Product Type
13.8.2.2. By End User
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2021
13.9.2.1. By Product Type
13.9.2.2. By End User
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2021
13.10.2.1. By Product Type
13.10.2.2. By End User
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2021
13.11.2.1. By Product Type
13.11.2.2. By End User
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2021
13.12.2.1. By Product Type
13.12.2.2. By End User
13.13. GCC Countries
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2021
13.13.2.1. By Product Type
13.13.2.2. By End User
13.14. South Africa
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2021
13.14.2.1. By Product Type
13.14.2.2. By End User
13.15. Israel
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2021
13.15.2.1. By Product Type
13.15.2.2. By End User
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Product Type
14.3.3. By End User
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Roche
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Gilead
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. GlaxoSmithKline
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Bristol-Myers Squibb
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Abbott
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. AstraZeneca
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Cipla
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Bayer AG
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Johnson & Johnson
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Merck & Co
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
15.1.11. AbbVie
15.1.11.1. Overview
15.1.11.2. Product Portfolio
15.1.11.3. Profitability by Market Segments
15.1.11.4. Sales Footprint
15.1.11.5. Strategy Overview
15.1.11.5.1. Marketing Strategy
15.1.12. Aurobindo Pharma
15.1.12.1. Overview
15.1.12.2. Product Portfolio
15.1.12.3. Profitability by Market Segments
15.1.12.4. Sales Footprint
15.1.12.5. Strategy Overview
15.1.12.5.1. Marketing Strategy
15.1.13. Dr. Reddy’s Laboratories Ltd
15.1.13.1. Overview
15.1.13.2. Product Portfolio
15.1.13.3. Profitability by Market Segments
15.1.13.4. Sales Footprint
15.1.13.5. Strategy Overview
15.1.13.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Anti-Viral Drugs Market Value (US$ Mn) Forecast by Region, 2016-2032
Table 2: Global Anti-Viral Drugs Market Value (US$ Mn) Forecast by Product Type, 2016-2032
Table 3: Global Anti-Viral Drugs Market Value (US$ Mn) Forecast by End User, 2016-2032
Table 4: North America Anti-Viral Drugs Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 5: North America Anti-Viral Drugs Market Value (US$ Mn) Forecast by Product Type, 2016-2032
Table 6: North America Anti-Viral Drugs Market Value (US$ Mn) Forecast by End User, 2016-2032
Table 7: Latin America Anti-Viral Drugs Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 8: Latin America Anti-Viral Drugs Market Value (US$ Mn) Forecast by Product Type, 2016-2032
Table 9: Latin America Anti-Viral Drugs Market Value (US$ Mn) Forecast by End User, 2016-2032
Table 10: Europe Anti-Viral Drugs Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 11: Europe Anti-Viral Drugs Market Value (US$ Mn) Forecast by Product Type, 2016-2032
Table 12: Europe Anti-Viral Drugs Market Value (US$ Mn) Forecast by End User, 2016-2032
Table 13: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 14: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) Forecast by Product Type, 2016-2032
Table 15: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) Forecast by End User, 2016-2032
Table 16: MEA Anti-Viral Drugs Market Value (US$ Mn) Forecast by Country, 2016-2032
Table 17: MEA Anti-Viral Drugs Market Value (US$ Mn) Forecast by Product Type, 2016-2032
Table 18: MEA Anti-Viral Drugs Market Value (US$ Mn) Forecast by End User, 2016-2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Anti-Viral Drugs Market Value (US$ Mn) by Product Type, 2022-2032
Figure 2: Global Anti-Viral Drugs Market Value (US$ Mn) by End User, 2022-2032
Figure 3: Global Anti-Viral Drugs Market Value (US$ Mn) by Region, 2022-2032
Figure 4: Global Anti-Viral Drugs Market Value (US$ Mn) Analysis by Region, 2016-2032
Figure 5: Global Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Region, 2022-2032
Figure 6: Global Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Region, 2022-2032
Figure 7: Global Anti-Viral Drugs Market Value (US$ Mn) Analysis by Product Type, 2016-2032
Figure 8: Global Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Product Type, 2022-2032
Figure 9: Global Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Product Type, 2022-2032
Figure 10: Global Anti-Viral Drugs Market Value (US$ Mn) Analysis by End User, 2016-2032
Figure 11: Global Anti-Viral Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 12: Global Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 13: Global Anti-Viral Drugs Market Attractiveness by Product Type, 2022-2032
Figure 14: Global Anti-Viral Drugs Market Attractiveness by End User, 2022-2032
Figure 15: Global Anti-Viral Drugs Market Attractiveness by Region, 2022-2032
Figure 16: North America Anti-Viral Drugs Market Value (US$ Mn) by Product Type, 2022-2032
Figure 17: North America Anti-Viral Drugs Market Value (US$ Mn) by End User, 2022-2032
Figure 18: North America Anti-Viral Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 19: North America Anti-Viral Drugs Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 20: North America Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 21: North America Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 22: North America Anti-Viral Drugs Market Value (US$ Mn) Analysis by Product Type, 2016-2032
Figure 23: North America Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Product Type, 2022-2032
Figure 24: North America Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Product Type, 2022-2032
Figure 25: North America Anti-Viral Drugs Market Value (US$ Mn) Analysis by End User, 2016-2032
Figure 26: North America Anti-Viral Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 27: North America Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 28: North America Anti-Viral Drugs Market Attractiveness by Product Type, 2022-2032
Figure 29: North America Anti-Viral Drugs Market Attractiveness by End User, 2022-2032
Figure 30: North America Anti-Viral Drugs Market Attractiveness by Country, 2022-2032
Figure 31: Latin America Anti-Viral Drugs Market Value (US$ Mn) by Product Type, 2022-2032
Figure 32: Latin America Anti-Viral Drugs Market Value (US$ Mn) by End User, 2022-2032
Figure 33: Latin America Anti-Viral Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 34: Latin America Anti-Viral Drugs Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 35: Latin America Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 36: Latin America Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 37: Latin America Anti-Viral Drugs Market Value (US$ Mn) Analysis by Product Type, 2016-2032
Figure 38: Latin America Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Product Type, 2022-2032
Figure 39: Latin America Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Product Type, 2022-2032
Figure 40: Latin America Anti-Viral Drugs Market Value (US$ Mn) Analysis by End User, 2016-2032
Figure 41: Latin America Anti-Viral Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 42: Latin America Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 43: Latin America Anti-Viral Drugs Market Attractiveness by Product Type, 2022-2032
Figure 44: Latin America Anti-Viral Drugs Market Attractiveness by End User, 2022-2032
Figure 45: Latin America Anti-Viral Drugs Market Attractiveness by Country, 2022-2032
Figure 46: Europe Anti-Viral Drugs Market Value (US$ Mn) by Product Type, 2022-2032
Figure 47: Europe Anti-Viral Drugs Market Value (US$ Mn) by End User, 2022-2032
Figure 48: Europe Anti-Viral Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 49: Europe Anti-Viral Drugs Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 50: Europe Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 51: Europe Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 52: Europe Anti-Viral Drugs Market Value (US$ Mn) Analysis by Product Type, 2016-2032
Figure 53: Europe Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Product Type, 2022-2032
Figure 54: Europe Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Product Type, 2022-2032
Figure 55: Europe Anti-Viral Drugs Market Value (US$ Mn) Analysis by End User, 2016-2032
Figure 56: Europe Anti-Viral Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 57: Europe Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 58: Europe Anti-Viral Drugs Market Attractiveness by Product Type, 2022-2032
Figure 59: Europe Anti-Viral Drugs Market Attractiveness by End User, 2022-2032
Figure 60: Europe Anti-Viral Drugs Market Attractiveness by Country, 2022-2032
Figure 61: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) by Product Type, 2022-2032
Figure 62: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) by End User, 2022-2032
Figure 63: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 64: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 65: Asia Pacific Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 66: Asia Pacific Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 67: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) Analysis by Product Type, 2016-2032
Figure 68: Asia Pacific Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Product Type, 2022-2032
Figure 69: Asia Pacific Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Product Type, 2022-2032
Figure 70: Asia Pacific Anti-Viral Drugs Market Value (US$ Mn) Analysis by End User, 2016-2032
Figure 71: Asia Pacific Anti-Viral Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 72: Asia Pacific Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 73: Asia Pacific Anti-Viral Drugs Market Attractiveness by Product Type, 2022-2032
Figure 74: Asia Pacific Anti-Viral Drugs Market Attractiveness by End User, 2022-2032
Figure 75: Asia Pacific Anti-Viral Drugs Market Attractiveness by Country, 2022-2032
Figure 76: MEA Anti-Viral Drugs Market Value (US$ Mn) by Product Type, 2022-2032
Figure 77: MEA Anti-Viral Drugs Market Value (US$ Mn) by End User, 2022-2032
Figure 78: MEA Anti-Viral Drugs Market Value (US$ Mn) by Country, 2022-2032
Figure 79: MEA Anti-Viral Drugs Market Value (US$ Mn) Analysis by Country, 2016-2032
Figure 80: MEA Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Country, 2022-2032
Figure 81: MEA Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Country, 2022-2032
Figure 82: MEA Anti-Viral Drugs Market Value (US$ Mn) Analysis by Product Type, 2016-2032
Figure 83: MEA Anti-Viral Drugs Market Value Share (%) and BPS Analysis by Product Type, 2022-2032
Figure 84: MEA Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by Product Type, 2022-2032
Figure 85: MEA Anti-Viral Drugs Market Value (US$ Mn) Analysis by End User, 2016-2032
Figure 86: MEA Anti-Viral Drugs Market Value Share (%) and BPS Analysis by End User, 2022-2032
Figure 87: MEA Anti-Viral Drugs Market Y-o-Y Growth (%) Projections by End User, 2022-2032
Figure 88: MEA Anti-Viral Drugs Market Attractiveness by Product Type, 2022-2032
Figure 89: MEA Anti-Viral Drugs Market Attractiveness by End User, 2022-2032
Figure 90: MEA Anti-Viral Drugs Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
